Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease

This study has been completed.
Sponsor:
Information provided by:
Takeda
ClinicalTrials.gov Identifier:
NCT00316992
First received: April 19, 2006
Last updated: May 31, 2010
Last verified: May 2010
  Purpose

The purpose of this study is to determine if ramelteon has respiratory depressant effects in subjects with moderate to severe chronic obstructive pulmonary disease.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Ramelteon and Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study of the Safety of Ramelteon in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Mean oxygen saturation during sleep for the entire night measured by pulse oximetry. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Mean oxygen saturation calculated for each hour of the night, as measured by pulse oximetry. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Mean oxygen saturation for rapid eye movement sleep stages, as measured by pulse oximetry. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Mean oxygen saturation for non- rapid eye movement sleep stages, as measured by pulse oximetry. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Minutes for which oxygen saturation was less than 80% as measured by pulse oximetry. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Minutes for which oxygen saturation was less than 90% as measured by pulse oximetry. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Apnea-hypopnea index as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Latency to persistent sleep as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Total sleep time as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Sleep efficiency as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Wake time after persistent sleep onset as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Number of awakenings after persistent sleep as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Percentage of time in rapid eye movement sleep as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Percentage of time in stage 1 sleep as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Percentage of time in stage 2 sleep as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Percentage of time in stage 3/4 sleep as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Latency to rapid eye movement sleep as determined by polysomnography. [ Time Frame: Crossover Period 1 Night 1 and Crossover Period 2 Night 1 ] [ Designated as safety issue: Yes ]
  • Subjective sleep latency as determined by postsleep questionnaire. [ Time Frame: Crossover Period 1 Morning 1 and Crossover Period 2 Morning 1 ] [ Designated as safety issue: No ]
  • Subjective total sleep time as determined by postsleep questionnaire. [ Time Frame: Crossover Period 1 Morning 1 and Crossover Period 2 Morning 1 ] [ Designated as safety issue: No ]
  • Subjective Sleep Quality as determined by postsleep questionnaire. [ Time Frame: Crossover Period 1 Morning 1 and Crossover Period 2 Morning 1 ] [ Designated as safety issue: No ]
  • Subjective number of awakenings as determined by postsleep questionnaire. [ Time Frame: Crossover Period 1 Morning 1 and Crossover Period 2 Morning 1 ] [ Designated as safety issue: No ]

Enrollment: 25
Study Start Date: April 2006
Study Completion Date: November 2006
Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramelteon 8 mg and Placebo Drug: Ramelteon and Placebo
Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
Other Names:
  • Rozerem™
  • TAK-375

Detailed Description:

About 30% of the adult population report sleep disturbance and 10% meet diagnostic criteria for chronic insomnia. While 20 -25% of these individuals have primary insomnia the vast majority have an additional condition such as chronic obstructive pulmonary disease. Several studies have looked at this and have estimated that 30% to 48% of the general population is affected at some time in their life with a form of insomnia that goes on for several months, and about one third of those are described as severely affected. Daytime symptoms of insomnia include tiredness, lack of energy, difficulty concentrating and irritability. Recent epidemiologic research focusing on the quality of life has identified significant insomnia related conditions or diseases that relate to work productivity, health care utilization, and risk of depression. Insomnia is associated with diminished work output, absenteeism and greater rates of accidents.

Ramelteon, is being developed as a sleep promoting agent based on agonism of melatonin receptor subtype 1 and 2. Ramelteon is marketed in the United States as Rozerem™ for the treatment of insomnia characterized by difficulty with sleep initiation.

Sleep problems are common in patients with chronic obstructive pulmonary disease. There is evidence that traditional hypnotics can cause adverse respiratory effects in insomniac populations with respiratory disorders, and so the safety and efficacy of new hypnotic agents must be ascertained in this group of patients.

This study will examine if ramelteon has respiratory depressant effects in subjects with moderate to severe chronic obstructive pulmonary disease. Study participation is anticipated to be about 6 weeks.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  • Body mass index between 18 and 34, inclusive.
  • Clinical history of chronic obstructive pulmonary disease and a confirmatory diagnosis based on pulmonary function tests performed at the Outpatient Screening Visit, with moderate to severe airflow limitation defined by: Moderate: forced expiratory volume in one second to forced vital capacity less than 70%; 50% less than forced expiratory volume in one second; less than 80% predicted. Severe: forced expiratory volume in one second to forced vital capacity less than 70%; forced expiratory volume in one second less than 50% predicted.
  • Post-bronchodilator forced expiratory volume in one second change from baseline of less than12% and not exceeding 200 ml at the Outpatient Screening Visit.
  • Oxygen saturation during wakefulness greater than 90% (both supine and sitting) as assessed by pulse oximetry at the Outpatient Screening Visit.
  • Oxygen saturation during sleep of greater than or equal to 80% for at least 75% of the recording period with no more than 5 continuous minutes less than 80% and with no oxygen saturation readings less than 70% as assessed by pulse oximetry at the Inpatient Screening Visit.

Exclusion Criteria

  • The health of subjects using nocturnal oxygen therapy would, in the investigator's opinion, be jeopardized by the removal of oxygen therapy during inpatient study visits.
  • Electrocardiographic evidence of right ventricular hypertrophy, or evidence of right heart failure.
  • Apnea hypopnea index (per hour of sleep) greater than 15 during polysomnography.
  • Has had an acute clinically significant illness within two weeks or has been hospitalized within four weeks of the Outpatient Screening Visit.
  • History of seizures (except childhood febrile seizures).
  • History of cancer, other than basal cell carcinoma, that has not been in remission for at least five years prior to the first dose of study drug. (This criterion does not include those subjects with basal cell or Stage 1 squamous cell carcinoma of the skin.)
  • History of drug addiction or drug abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised.
  • History of alcohol abuse within the past 12 months, as defined in
  • Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised and/or regularly consumes more than 14 alcoholic drinks per week, or consumed any alcoholic drinks within six hours of any PSG visits.
  • Will not refrain from use of tobacco products while in the sleep laboratory.
  • Any clinically important abnormal finding, other than chronic obstructive pulmonary disease, as determined by medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
  • Current significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease, unless currently controlled and stable with protocol-allowed medication 30 days prior to the Inpatient Screening Visit.
  • Hematocrit value greater than 55% at the Outpatient Screening Visit.
  • Positive hepatitis panel including anti-hepatitis A virus (only immunoglobulin M is exclusionary), hepatitis B surface antigen, or anti-hepatitis C virus.
  • Alanine transaminase level of greater than three times the upper limit of normal, active liver disease, jaundice or any clinically significant abnormal laboratory findings as determined by the investigator.
  • Donated more than 400 mL of blood within the 90 days preceding the beginning of the study.
  • Positive urine drug screen for drugs known to alter sleep-wake function (eg, barbiturates, opiates, amphetamines, cannabinoids and alcohol) at screening, or a positive breathalyzer test for alcohol at any check-in.
  • Known hypersensitivity to ramelteon or related compounds, including melatonin.
  • Known hypersensitivity to albuterol or related compounds.
  • Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to the first dose of single-blind study medication, whichever is longer.
  • Unable to discontinue the use of hypnotics for the duration of the study.
  • Has used melatonin, or other drugs or supplements known to affect sleep-wake function, within one week (or five half-lives of the drug, whichever is longer) prior to the first dose of single-blind study medication.
  • Any additional condition(s) that in the Investigator's opinion would prohibit the subject from completing the study or not be in the best interest of the subject.
  • Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Within one week of single-blind medication and during the entire study.

      • Hypnotics
      • Sedating Antidepressants
      • Sedating H1 antihistamines
      • Respiratory stimulants
      • Muscle relaxants
      • The use of albuterol is acceptable during reversibility testing at the Outpatient Screening Visit.
    • Melatonin and all other drugs or supplements known to affect sleep/wake function will be prohibited within one week of the first dose of single-blind medication and during the entire study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00316992

Locations
United States, Alabama
Birmingham, Alabama, United States, 35213
United States, California
Los Angeles, California, United States
Santa Monica, California, United States, 90404
United States, Florida
Naples, Florida, United States, 34110
St. Petersburg, Florida, United States, 33707
United States, Kentucky
Louisville, Kentucky, United States, 40217
United States, Nebraska
Lincoln, Nebraska, United States, 68510
United States, New York
New York, New York, United States, 10025
Sponsors and Collaborators
Takeda
Investigators
Study Director: Medical Director Clinical Science Takeda Global Research and Development
  More Information

Additional Information:
Publications:
Responsible Party: Sr. VP, Clinical Science, Takeda Global Research & Development, Inc.
ClinicalTrials.gov Identifier: NCT00316992     History of Changes
Other Study ID Numbers: 01-05-TL-375-068, U1111-1115-1960
Study First Received: April 19, 2006
Last Updated: May 31, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Insomnia
Chronic Obstructive Pulmonary Disease
Drug Therapy

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on October 16, 2014